Install
- 17,419articles · 30d
- 3+ hour agolatest article
- Aug 15, 2026earliest in window
- 94%with images · 8 videos
- 143avg words
- business 9,961
- markets 8,262
- stock 5,759
- tmt newswire 4,468
- globenewswire 4,019
- finance 3,863
- technology 2,683
- stocks 2,562
- 2026 2,329
- economy 2,115
- business news 1,844
- earnings 1,764
- autre 1,643
- investing 1,507
- politics 1,424
- artificial intelligence 1,418
- (midwest communications 1,285
- europe 1,232
- stock market 1,090
- united states 1,088
- Economy, Business & Finance 16,478
- Finance & Business 15,910
- News 9,582
- Finance 4,491
- Business & Industrial 1,860
- Industrial 491
- Health & Wellness 289
- Politics 219
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
TNXP: Strong sales growth, pipeline progress, and robust cash position drive optimism for future milestones
3+ day, 13+ hour ago (79+ words) tradingview.com TONMYA's launch for fibromyalgia has shown strong early sales growth and broadening access, with a unique mechanism and favorable tolerability. The pipeline includes a phase II-ready Lyme disease antibody and an anti-CD40 ligand program for transplantation, supported by…...
NAMS: PREVAIL’s interim analysis and upcoming RUBIN data position obicetrapib for a differentiated launch
4+ day, 13+ hour ago (86+ words) TradingView NAMS: PREVAIL’s interim analysis and upcoming RUBIN data position obicetrapib for a differentiated launch Obicetrapib, a differentiated CETP inhibitor, is nearing key readouts from the PREVAIL cardiovascular outcomes trial and RUBIN diabetes study, with plans for launch in 12–18 months....
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines
5+ day, 14+ hour ago (142+ words) TradingView Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines Adicet Bio posted a September 2026 investor presentation highlighting prula-cel clinical progress and IND-cleared ADI-212 with near-term clinic timelines. - Posted investor presentation on Sept 8, 2026; furnished as Exhibit 99.1 under…...
TABLE-Nadex -Q1 group results — TradingView News
6+ day, 4+ hour ago (9+ words) TABLE-Nadex -Q1 group results TradingView TABLE-Nadex -Q1 group results...
Revenio Group: Visionix integration advances, synergies materialize, and 2026 guidance targets strong sales growth
5+ day, 19+ hour ago (84+ words) TradingView Revenio Group: Visionix integration advances, synergies materialize, and 2026 guidance targets strong sales growth Integration of Visionix is ahead of plan, with EUR 5 million in synergies realized and flat H1 performance as expected. Q2 net sales rose 48.1% due to the acquisition, but…...
SynAct on phase III plans following new ADVANCE data
6+ day, 20+ hour ago (147+ words) TradingView SynAct on phase III plans following new ADVANCE data SynAct Pharma has presented a post-hoc analysis of the phase IIb ADVANCE study with resomelagon in rheumatoid arthritis. The new data clarify previous placebo responses and reinforce the drug’s therapeutic…...
ATORX: Pivot to HLX22 royalties, winding down operations, and rights issue to fund until 2030 revenues
2+ week, 4+ day ago (76+ words) TradingView ATORX: Pivot to HLX22 royalties, winding down operations, and rights issue to fund until 2030 revenues Strategic shift to focus on HLX22 royalties after discontinuing mitazalimab development due to KRAS inhibitor advances. Rights issue approved to fund operations until HLX22 launch, with first…...
ATORX: Pivot to HLX22 royalties, winding down operations, and raising capital to fund until 2030
2+ week, 4+ day ago (70+ words) TradingView ATORX: Pivot to HLX22 royalties, winding down operations, and raising capital to fund until 2030 Strategic shift to focus on HLX22 royalties after discontinuing mitazalimab development due to new KRAS inhibitor data. Rights issue and cost reductions aim to fund operations until…...
Abelco has completed registrations following the Annual General Meeting
2+ week, 5+ day ago (120+ words) Abelco Investment Group AB (“Abelco” or the “Company”) announces that the required registrations resulting from the resolutions adopted at the Annual General Meeting have now been completed with the Swedish Companies Registration Office. The registrations mean that the resolved changes…...
Xpeng Inc expected to post a loss of 56 fen a share - Earnings Preview
3+ week, 2+ day ago (29+ words) TradingView Xpeng Inc expected to post a loss of 56 fen a share - Earnings Preview...